Kornimate/medical-research-clean huggingface dataset:
comparison of chen's u-suture technique with duct-to-mucosa anastomosis and invagination pancreaticojejunostomy after pancreaticoduodenectomy

Conditions: Pancreaticoduodenectomy

Summary: data of patients treated with pancreaticoduodenectomy in 21 hospitals from january 2014 to december 2019 were retrospectively collected and classified to chen's group, duct-to-mucosa group and invagination group according to different pancreaticojejunostomy. propensity score matching analysis was performed to balance the baseline differences among three groups. the surgical outcomes were compared. independent risk factors for postoperative pancreatic fistula were confirmed by logistic regression analysis, and subgroup analysis was also conducted.


Eligibility criteria:
inclusion criteria: * open pancreaticoduodenectomy * chen's u-suture technique or invagination or duct-to-mucosa anastomosis exclusion criteria: * missing data
clinical outcome after lumbar fusion

Conditions: Chronic Low Back Pain

Summary: the main objective of this prospective study is to compare the clinical outcomes after lumbar fusion for chronic low back pain using the four techniques commonly employed in our surgical practice. lumbar fusion stops motion at a painful vertebral segment, which can decrease back pain. the four techniques are standard transforaminal lumbar interbody fusion (s tlif), minimally invasive transforaminal lumbar interbody fusion (mi tlif), extreme lateral interbody fusion (xlif), and axial lumbar interbody fusion (axialif). each differ in where incisions are made and level of invasiveness; not all may be implemented in each surgical case. the four different techniques are all standard approaches with different advantages and have yet to be compared in efficacy for relieving chronic low back pain.


Eligibility criteria:
inclusion criteria: * severe chronic low back pain (at least 7 out of 10 on the vas scale). * age: 25-65 years. * pain duration at least 2 years. * the treating surgeon should interpret the pain as emanating from l4-s1. * the patient must have had unsuccessful maximal possible conservative (non surgical) treatment for at least one year. * radiographic evidence (mri, ct, ct-spect, and/or plain films) of degenerative changes ("spondylosis") exclusion criteria: * psychiatric illness or evidence of emotional instability. * previous spine surgery except for successful removal of a herniated disc more than 2 years before entering the study and with no persistent nerve root symptoms. * specific radiologic findings, such as fractures, infection, inflammatory process, or neoplasm. * obvious painful and disabling arthritic hip joints and anamnestic and radiologic signs of spinal stenosis. * involvement in workman's comp or litigation.
clinical performance of extended all-ceramic fixed partial dentures based on zircon-oxide ceramics.

Conditions: Tooth Loss, Teeth Replaced Using All Ceramic FPDs

Summary: fixed-partial dentures fabricated of zircon-oxide ceramics were introduced in dentistry some time ago. however, the survival rate of all-ceramic extended (up to 47mm) fixed-partial dentures is unknown. the hypothesis was that long fdps fabricated of zirkon-oxide withstand masticatory forces in the posterior and anterior regio of the jaw.

30 patients with at least 2 missing posterior or anterior teeth will be included in the study. all patients will receive all-ceramic fixed partial dentures.

Eligibility criteria:
inclusion criteria: * all patients older 18 years * at least two missing posterior teeth * tooth wear\<3 exclusion criteria: * bruxism * mental disorders * pregnancy * tooth mobility\>1

Keywords: fpd, all-ceramic
trial of smoking cessation programs in black churches

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Heart Disease Risk Reduction

Summary: to provide a comprehensive description of smoking beliefs and behavior among rural blacks, and to test the effectiveness of smoking cessation strategies delivered through black churches.

design narrative: two demographically similar rural counties in central virginia were compared, one intervention and one control site. in each country, two cohorts were assembled, a random sample of all black smokers (the community cohort), and all members of randomly sampled black churches (the church cohort). the descriptive component of the study elicited the knowledge, beliefs, attitudes, and behavior concerning smoking from these cohorts. cardiovascular risk factors, including blood pressure and cholesterol levels, were also determined in the community cohort. for the experimental component, a variety of interventions which have proven to be efficacious in other settings were implemented through black churches. these included fostering a supportive environment, distributing self-help materials, and providing individual support and counselling through the use of peer facilitators. the results of the baseline psychosocial survey were used to modify these methods for local use. they were then implemented in a culturally appropriate fashion at the intervention sites. baseline smoking rates were determined using the initial surveys in both counties. smokers were surveyed again at the end of the interventions and one year later to establish one-year abstinence rates. these were used as the primary outcome variables for the analysis of effect. the principal effect of the interventions were measured by comparing smoking abstinence rates between the church cohorts in the intervention and control counties. due to the extended nature of the social networks associated with the churches, the interventions may also have had an effect on individuals not directly exposed, and this was determined by comparing the outcomes in the community cohorts. finally, the associations between the baseline psychosocial and physiologic variables, exposure to the interventions, and smoking cessation behavior were also analyzed, to characterize on a population basis those who were and were not influenced by these church-based programs.

Eligibility criteria:
no eligibility criteria
covered self-expandable metallic stents insertion using clips and suture materials for preventing migration

Conditions: Gastroduodenal Anastomosis

Summary: in patients of subtotal gastrectomy with billroth-i or billroth-ii anastomosis, anastomosis site stricture is very severe complication. it can improve by temporary through the scope covered metallic stent. it is very effective procedure about the stricture. but stent migration is very severe complication. herein the investigators suggest newly method to prevent the stent migration. fixation of stent by hemoclip is effective method to prevent stent migration. but it is difficult to remove stent after resolved stricture. so the investigators add the suture between hemoclip and stent. and the investigators cut the suture when stent removal.


Eligibility criteria:
inclusion criteria: * subtotal gastrectomy with billroth-i or billroth-ii anastomosis * symptom of gastric outlet obstruction * anastomosis site stricture after surgery exclusion criteria: * patients of the impossible stent insertion due to other complication * foreigner * no agree a concent

Keywords: anastomosis site structure stent insertion stent migration
oct- versus angiography-guided paclitaxel drug-coated balloon angioplasty in de novo coronary artery

Conditions: Coronary Artery Disease

Summary: oct allows precise evaluation of intimal injury after lesion preparation and may improve the acute results and long-term outcomes after paclitaxel drug-coated balloon angioplasty. this prospective multicenter cohort study aims to assess the efficacy and safety of oct- versus angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery after lesion preparation with scoring balloon.


Eligibility criteria:
inclusion criteria: 1. 18 to 85 years old 2. patients have ischemic symptoms or evidence of myocardial ischemia (inducible or spontaneous) in the presence of a stenosis of at least 50% in a native coronary artery, including stable angina, unstable angina, or silent ischemia. 3. reference vessel diameter \>2.5 mm, and \<4.0 mm. 4. lesion length of \<22 mm 5. written informed consent exclusion criteria: 1. myocardial infarction within 4 weeks, including st-elevation myocardial infarction and non-st-elevation myocardial infarction 2. cardiogenic shock (systolic arterial pressure \<90mmhg), congestive heart failure (nyha or killip≥3) 3. chronic kidney disease (egfr \<30 ml/min) 4. lesion length \>22 mm, or vessel diameters of \ 4.0 mm 5. stents covering a major side branch (\>2 mm) 6. left main lesion 7. graft lesion 8. aortic-coronary ostial lesion 9. in-stent restenotic lesion 10. chronic total occlusion 11. severe calcified lesions. 12. visible angiographic thrombus 13. severe comorbidities: eg. malignancy (life expectancy \<2 years)
retinal nerve fiber layer thickness analysis with cirrus hd oct versus stratus optical coherence tomography (oct)

Conditions: Glaucoma

Summary: the cirrus hd oct, a new spectral domain optical coherence tomography (oct), has better resolution than the previous time domain stratus oct. discriminating ability of these two octs for diagnosis of glaucoma and judgement of disease progression will be studied.

the cirrus hd oct is a new spectral domain oct. even though its resolution and speed are much better than the previous time domain stratus oct, its diagnostic power for glaucoma detection and judgement of disease progression should be directly compared with stratus oct. in the present study, we will review the data of peripapillary retinal nerve fiber layer thickness measurement using the cirrus hd oct and stratus oct. their discriminating ability for diagnosis of glaucoma and judgement of disease progression will be compared using the roc curves and cohen's kappa.

Eligibility criteria:
inclusion criteria: * retinal nerve fiber layer analysis with cirrus oct and stratus oct within 1 month exclusion criteria: * intraocular surgeries history * dm * high refractive error ( \ + 4.00 diopters) * media opacity

Keywords: glaucoma retinal nerve fiber layer cirrus oct stratus oct
tolerance study of the dietary supplement valedia

Conditions: Overweight

Summary: the objectives of this clinical study are to determine the tolerance of dietary supplement valedia (blend of plant extracts) through the evaluation of several parameters : * various blood biological parameters for tolerance (preprandial): blood glucose, insulin, fructosamine, total cholesterol, triglycerides, hdl-cholesterol, ldl-cholesterol, oxidized ldl, us-crp, creatinine, asat, alat, ggt, phosphatase alcaline, bilirubine, urea. * urinary parameters: urea, creatinine. * hemodynamic parameters: heart rate and blood pressure. * cardiac function: ecg. * weight.


Eligibility criteria:
main inclusion criteria: * 25 \<= bmi \< 30 kg.m2 main exclusion criteria: * asat \<= 1,55 microkat/l * alat \<= 1,70 microkat/l * ggt \<= 2,55 microkat/l * 55 \<= creatinine \<= 104 micromol/l (+- 10%) * bilirubin \< 17,1 micromol/l (+- 10%) * 1,7 \<= urea \<= 8,3 mmol/l (+- 10%) * us-crp \<= 5 mg/l (+- 10%) * 0,70 \<= fasting glycemia \<= 1,25 g/l (+- 10%) * hba1c \<= 6% * medications for diabetes and/or dyslipidemia
safety and immunogenicity of imvamune® (mva-bn®) smallpox vaccine in hiv infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in hiv infected populations. subjects will receive two vaccinations


Eligibility criteria:
* genders eligible for study: both * age: between 18 and 55 years * healthy volunteers are accepted inclusion criteria: * subjects tested positive for hiv-1 infection (hiv-infected subjects). * subjects that are tested negative for hiv (healthy subjects). * either on stable antiretroviral therapy or not on antiretroviral therapy. * cd4 cells \> = 200 - 750/µl. * subjects must be in good general health except for hiv infection. * women must not be pregnant and use an acceptable method of contraception. exclusion criteria: * impairment of immunologic function (other than hiv infection). * history of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure. * uncontrolled serious infection. * history of or active autoimmune disease. * history or clinical manifestation of clinically significant and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders. * history of an immediate family member (father, mother, brother, or sister) who has had onset of ischemic heart disease before the age of 50 years. * high risk of developing a myocardial infarction or coronary death. * history of intravenous drug abuse (within the last 12 months). * known allergy to egg or aminoglycoside (gentamicin). * history of anaphylaxis or severe allergic reaction. * subjects undergoing treatment for tuberculosis infection or disease. * chronic administration of systemic immuno-suppressants.

Keywords: hiv treatment experienced treatment vaccinia naive
flex intramedullary rod study

Conditions: Osteoarthritis of the Knee; Arthroplasty, Replacement, Knee

Summary: the purpose of this study is to compare the effect of post-operative rom between flex im rod and rigid im rod, to collect bone morphology of japanese lower extremity and to research the incidence of overhung with flex im rod.


Eligibility criteria:
inclusion criteria: 1. patient has signed an institutional review board (irb) approved, study specific informed patient consent form. 2. patient is a male or non-pregnant female age 20 years or older. 3. patient is candidate for primary total knee arthroplasty (tka). 4. patient whose preoperative range of motion (rom) is over 110 degree. 5. patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation. exclusion criteria: 1. revision cases 2. patients that use bone wedges or allograft due to bone loss. 3. patient has a body mass index (bmi) \>40. 4. patient has an active or suspected latent infection in or about the affected knee joint at time of study device implantation. 5. patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device. 6. patient is diagnosed with a systemic disease (e.g. lupus erythematosus) or a metabolic disorder (e.g. paget's disease) leading to progressive bone deterioration. 7. patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days). 8. patient has failed unicondylar knee prosthesis. 9. patient has a known sensitivity to device materials. 10. patient who are inappropriate for participating in the study in the judgment of the investigator.
nutrition and metabolic prehabilitation in hsct patients uk and roi. bsbmt multi-centre survey.

Conditions: Haematological Malignancy; Bone Marrow Transplant Complications; Stem Cell Transplant Complications; Nutrition Aspect of Cancer; Nutritional and Metabolic Disease; Exercise Interventions; Prehabilitation

Summary: to explore current practices of nutrition and metabolic screening, assessment and management prior to haematopoietic stem cell transplant (hsct) in uk and roi transplant centres. nutrition and metabolic parameters assessed in the survey include glycaemic control, lipid function, liver function, nutritional screening, nutritional assessment, nutrition intervention (tube feeding, diet, micronutrient) and exercise. this work will be used to inform the design of a uk dual centre feasibility study of personalised nutrition and metabolic care for hsct patients prior to transplantation.


Eligibility criteria:
inclusion criteria: * bsbmt registered adult hsct centres (including tya services where patients have opted to be treated in an adult service pathways) * centres delivering either autologous or allogeneic stem cell transplants exclusion criteria: * all paediatric hsct services

Keywords: nutrition metabolism exercise bone marrow transplant stem cell transplant autologous transplant allogeneic transplant prehabilitation
erector spinae plane block for lumbar disc hernia repair

Conditions: Postoperative Pain

Summary: pain management after lomber disc hernia repair surgery is a challenging issue for anesthetists. erector spinae plane block is a novel analgesic technique which could be used for this purpose. primary aim of this double blinded randomized controlled study is to compare the analgesic efficacy of this new block technique with control group in this group of patients.


Eligibility criteria:
inclusion criteria: * asa i-ii * age 18-65 years * undergoing elective lomber disc hernia exclusion criteria: * obesity * asa iii - iv * infection of the skin at the site of needle puncture area * patients with known allergies to any of the study drugs * coagulopathy

Keywords: lomber disc hernia erector spinae plane block postoperative pain
growth hormone treatment on phosphocreatine recovery in obesity

Conditions: Obese; Growth Hormone Secretion Abnormality

Summary: obesity is associated with reduced growth hormone (gh) secretion. reduced gh secretion in obesity is associated with increased cardiovascular disease risk. however, it is not yet known how reduced gh increases cardiovascular disease risk in obesity. the investigators hypothesize that reduced gh contributes to dysfunction of the mitochondria. therefore, the investigators hypothesize that treatment of obese subjects with reduced gh secretion with gh will improve mitochondrial function and that this improvement in mitochondrial function will contribute, in part, to the effects of gh to improve metabolic parameters in obesity. the investigators propose to study skeletal muscle mitochondria in obese subjects with reduced gh secretion using magnetic resonance spectroscopy and muscle biopsies before and after treatment with gh.


Eligibility criteria:
inclusion criteria: 1. men age 18-60 years old 2. bmi ≥ 30 kg/m2 3. waist circumference ≥ 102 cm 4. peak gh value of ≤ 4.2 μg/l on standard ghrh-arginine stimulation test exclusion criteria: 1. obesity due to a known secondary cause (cushing's syndrome, hypothyroidism, etc) or a history of gastric bypass procedure. 2. subjects who have a known history of diabetes, fasting blood sugar \>125 mg/dl or using any anti-diabetic drugs. 3. use of aspirin, clopidogrel (plavix), warfarin (coumadin) or other anti-coagulants 4. subjects on testosterone, glucocorticoids, anabolic steroids, ghrh, gh or igf-1 within 3 months of enrollment. 5. changes in lipid lowering or anti-hypertensive regimen within 3 months of screening 6. history of pituitary tumor, hypopituitarism, pituitary surgery, pituitary/brain radiation or traumatic brain injury or any other condition known to affect the gh axis. 7. severe chronic illness including hiv, active malignancy or history of colon cancer. 8. hemoglobin \ 2.5 x upper limit normal, creatinine \>1.5 mg/dl, or psa \>5 ng/ml. 9. subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit. 10. any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient. 11. contraindications to mri scanning.

Keywords: growth hormone gh obesity mitochondrial function reduced growth hormone secretion
internal radiation therapy in treating patients with low-risk prostate cancer

Conditions: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer

Summary: this phase ii trial studies how well internal radiation therapy works in treating patients with low-risk prostate cancer. internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells.

primary objectives: i. to determine long term 5 year prostate specific cancer (psa) biochemical control using the phoenix definition of psa nadir + 2 of targeted hemi-gland brachytherapy. secondary objectives: i. to assess acute and late toxicity outcomes following targeted brachytherapy according to national cancer institute (nci) common terminology criteria for adverse events (ctcae) v4.0. ii. to determine changes from baseline in health-related quality of life indicators using the validated expanded prostate cancer index composite (epic) questionnaire, international index of erectile function (iief) questionnaire, and international prostate symptom score (ipss) questionnaire. iii. to assess the potential value of multiparametric magnetic resonance imaging, including dynamic contrast enhancement perfusion imaging and diffusion tensor neurovascular tactographic imaging in predicting the development of equivocal disease (ed) following radiation treatment. outline: patients undergo 3 fractions of image-guided high-dose rate (hdr) brachytherapy over 2 days. after completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary non-metastatic adenocarcinoma of the prostate * unilateral prostate cancer as determined by prostate biopsy * less than or equal to 3 positive biopsy cores * no biopsy core \>= 50% positive for cancer * karnofsky performance status (kps) \>= 70 * at least a 12 core prostate biopsy; if this was not performed then it will be repeated here at university of california at los angeles (ucla) * artemis guided biopsy of any suspicious target lesions as identified on multiparametric (mp)-magnetic resonance imaging (mri) * clinical stage t1c or t2a * psa \< 10 ng/ml * gleason score 3+3=6 exclusion criteria: * patients who have previously received radiation therapy to the pelvis * refusal to sign the informed consent * patients who are participating in a concurrent treatment protocol
the effect of intravenous mannitol plus saline on the prevention of cisplatin-induced nephrotoxicity: a randomized, double-blind, placebo controlled trial

Conditions: Cis-Platinum Nephropathy; Mannitol Adverse Reaction

Summary: this study include cancer patients who had received chemotherapy that include cisplatin. patients were randomly assigned to either a mannitol 20 g intravenous single dose after cisplatin or a placebo (saline). the primary outcome was to compare acute kidney injury (aki), which was defined as increase creatinine 0.3 mg/dl in 48 hours by kdigo criteria using serum creatinine and 24 hour urine creatinine to calculated.


Eligibility criteria:
inclusion criteria: 1. patients who was at least 18 years old. 2. patients who had been diagnosed with cancer proven by tissue biopsy. 3. patients who were scheduled to receive cisplatin or combination of cisplatin and other chemotherapy, which the dose of cisplatin was not exceeded 100 mg/m2. 4. patients were required to have a normal renal function (gfr \> 60 ml/min/1.73m2). 5. patients with an eastern cooperative oncology group (ecog) score ≤ 2. 6. patients with normal serum sodium and serum potassium level. exclusion criteria: 1. patients with any acute kidney injury event before randomized into trial not more than 6 months. 2. patients with chronic kidney disease or hydronephrosis. 3. patients with history of nephrectomy. 4. patients who had previously received immunosuppressants for any immune deficiency disease. 5. patients with who had received chemotherapy which induce nephrotoxicity. 6. patients with had received drug which is nephrotoxic (amphotericin b, aminoglycoside or non-steroidal anti-inflammatory drug). 7. patients who had cirrhosis with child pugh score more than 7. 8. patients with or had a known allergy to cisplatin or mannitol. 9. patients with chronic heart failure who cannot received fluid more than 1 liter. 10. patients who were not comfortable to follow up at clinic for long term outcome.